FDA Brief

Warning letters Animal

FDA warning letter to

Neogen Corporation

High riskIssued Sep 23Posted Sep 29Center for Veterinary Medicine

FDA found Neogen's HYCOAT animal drug contaminated and made under insanitary conditions after horse deaths.

What happened

FDA began a multistate investigation after more than 95 serious adverse events in horses. FDA collected samples, inspected the contract manufacturer's facility, and reviewed epidemiological and clinical evidence. FDA found HYCOAT lot 5A001, labeled sterile, contained viable fungi, and found the contract manufacturer made HYCOAT under insanitary conditions; Neogen recalled several lots on January 28, 2026.

What FDA found

  1. FDA's lab found viable fungi in HYCOAT lot 5A001 even though it was labeled sterile, so the product's purity and quality fell below what it claimed.

    FD&C Act section 501(c), 21 U.S.C. 351(c); section 501(a)(1), 21 U.S.C. 351(a)
  2. FDA found the contract manufacturer made HYCOAT under insanitary conditions, including inadequate cleaning, air and environmental monitoring, personnel sampling, smoke studies, gowning, and media fills.

    FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)
  3. Neogen, as the distributor, did not provide adequate quality oversight of the contract manufacturer that made HYCOAT.

  4. HYCOAT's labeling gives little or no instructions for several serious indications and does not say it is only for use by or under a licensed veterinarian.

    FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)
  5. HYCOAT is labeled 'sterile solution' but FDA testing found contamination, making the labeling false or misleading.

    FD&C Act section 502(a), 21 U.S.C. 352(a)
  6. Neogen introduced adulterated and misbranded HYCOAT into interstate commerce.

    FD&C Act section 301(a), 21 U.S.C. 331(a)

What FDA wants

Within 15 working days of receipt, notify FDA in writing of the specific corrective steps taken, how recurrence will be prevented, and include supporting documents; if actions cannot be completed in that time, explain the delay and give a completion date.

Who should pay attention

  • veterinarians using HYCOAT
  • distributors and brands relying on contract manufacturers for sterile animal drugs
  • horse owners and equine practices

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk